Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human single-chain Fv intrabodies counteract <i>in situ</i> huntingtin aggregation in cellular models of Huntington's disease

10 Apr 2001

Abstract excerpt

This investigation was pursued to test the use of intracellular antibodies (intrabodies) as a means of blocking the pathogenesis of Huntington's disease (HD). HD is characterized by abnormally elongated polyglutamine near the N terminus of the huntingtin protein, which induces pathological protein-protein interactions and aggregate formation by huntingtin or its exon 1-containing fragments. Selection from a large...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Muscle Physiology and Disorders
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11296304
DOI: 10.1073/pnas.071058398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human single-chain Fv intrabodies counteract <i>in situ</i> huntingtin aggregation in cellular models of Huntington's diseasePMID 11296304Read ↗

Intrabody applications in neurological disorders: progress and future prospectsSemantic proximity Read ↗

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Semantic proximity Read ↗

Development of a novel VHH intrabody targeting the N17 region of huntingtin exon 1 protein that prevents inclusion body formationSemantic proximity Read ↗

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersSemantic proximity Read ↗

Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.Semantic proximity Read ↗

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Semantic proximity Read ↗

Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.Semantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.Semantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and OncologySemantic proximity Read ↗

Engineered Nanobodies With Programmable Target Antigen Proteolysis (Ptap) Fusions Regulate Intracellular Alpha-synuclein in Vitro and in VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.